Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program☆
Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program☆. // ESMO Real World Data and Digital Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949820126001128?dgcid=rss_sd_all
Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program☆. ESMO Real World Data and Digital Oncology. https://www.sciencedirect.com/science/article/pii/S2949820126001128?dgcid=rss_sd_all
“Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program☆.” ESMO Real World Data and Digital Oncology.
@article{article44828,
title = {Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program☆},
journal = {ESMO Real World Data and Digital Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949820126001128?dgcid=rss_sd_all}
}